知镜 Cognispect · 医学文献与研究工作台

Finerenone Use in Heart Failure Patients with Type 2 Diabetes and Kidney Disease: An Analysis of the FINE-TURK Registry.

Yadigar S, Akgür S, Güvenç TS, Sezen M, Özcan B, Yıldırım Ayaz E, Doğantekin B, Atay İ, Değer SM, Demir M, Koyuncu S, Yılmaz Ü, İnci A, Çolak H, Demirelli B, Tuğlular S, Oğuz EG, Aylı MD, Avanaz E, Yılmaz F, Doğan B, Karaköse S, Karakan MŞ, Demirci BG, Türkmen K, Baloğlu İ, Batmazoğlu M, Mert M, Aydın E, Aydın FY, Parmaksız E, Özdemir P, Ediz B, Aydın Z, Demir ME, Sezer S, Ünver S, Baykal Ö, Akman Çakmak B, Altuntaş A, İslam M, Koçak Yücel FS, Mert M, Dursun B, Eren N, Demir SB, Güven AT, Bilgiç MA, Erdut A, Keskin G, Şahin AZ, Horoz M, Tekinyıldız M, Duranay M, Yalın SF, Altunok M, Sarı F, Sarı R, Torun D, Kahvecioğlu S, Yalçınkaya AS, Akagün T, Çelik H, Kazan S, Öztürk İ, Polat M, Aydın MF, Meşe M, Yavuz Umut MH, Demirezen A, Derici Ü, Altun E, Şengül E, Bakırdöğen S, Kara E, Akgöl C, Aykent MB, İlter A, Ekmekçi A, Ulu S, Arıcı M, Arı Bakır E.
Cardiovascular drugs and therapy · 2026-09-10 · PMID 42720721

文献摘要

Background Finerenone, a non-steroidal mineralocorticoid receptor antagonist, improves cardiorenal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. However, real-world data on its use in patients with concomitant heart failure remain limited. This study aimed to evaluate the baseline characteristics and short-term renal safety and efficacy of finerenone in patients with type 2 diabetes, kidney disease, and heart failure from the FINE-TURK Registry. Methods This was a retrospective, multicenter, observational registry analysis conducted across 56 centers in Türkiye. Among 1,168 patients initially enrolled, 918 patients with available heart failure status and ejection fraction data were included. Patients were categorized according to the presence of heart failure, and heart failure patients were further classified as HFrEF or HFmrEF/HFpEF. Three-month changes in serum potassium, estimated glomerular filtration rate, and albuminuria were assessed. Safety endpoints included serum potassium ≥ 5.5 mEq/L and eGFR ≤ 25 mL/min/1.73 m² at three months. The primary renal efficacy endpoint was a > 30% reduction in albuminuria from baseline. Results Of 918 patients, 133 had heart failure. Patients with heart failure were older and had lower baseline eGFR compared with those without heart failure. They were also more likely to receive a lower starting dose of finerenone. At three months, changes in serum potassium, eGFR, and albuminuria were not significantly different between patients with and without heart failure. No excess risk of hyperkalemia or worsening renal function was observed in the heart failure group. In adjusted analyses, heart failure was associated with a greater likelihood of achieving a > 30% reduction in albuminuria. No significant differences in short-term renal safety or efficacy outcomes were observed between HFrEF and HFmrEF/HFpEF subgroups. Conclusions In this nationwide real-world registry, patients with heart failure who were treated with finerenone had a higher-risk baseline profile, including older age and lower eGFR. Despite this, finerenone was not associated with increased short-term renal safety concerns and was linked to a clinically meaningful reduction in albuminuria. These findings support the short-term renal safety and potential efficacy of finerenone in patients with type 2 diabetes, kidney disease, and heart failure.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。